UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
(Amendment No. )
Filed by the
Registrant
x
Filed by a party other than the
Registrant
o
Check the appropriate box:
o
Preliminary
Proxy Statement
o
Confidential,
for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
o
Definitive
Proxy Statement
x
Definitive
Additional Materials
o
Soliciting
Material Pursuant to
§ 240.14a-12
FOREST LABORATORIES, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy
Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
x
|
No fee required.
|
o
|
Fee computed on table below per Exchange Act
Rules 14a-6(i)(1)
and 0-11.
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
(3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act
Rule 0-11
(set forth the amount on which the filing fee is calculated and
state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
o
Fee
paid previously with preliminary materials.
o
Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its
filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
Important Additional Information
Forward Looking Information
Except for the historical information contained herein, this document contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a
number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive products and pricing, the timely
development and launch of new products, changes in laws and regulations affecting the healthcare industry
and the risk factors listed from time to time in Forest Laboratories' Annual Reports on Form 10-K (including
the Annual Report on form 10-K for the fiscal year ended March 31, 2011), Quarterly Reports on Form 10-Q,
and any subsequent SEC filings.
Important Additional Information
Forest Laboratories, its directors, director nominees and certain of its executive officers may be deemed to be
participants in the solicitation of proxies from Forest shareholders in connection with the matters to be
considered at Forest Laboratories' 2011 Annual Meeting. On July 18, 2011, Forest Laboratories filed its
definitive proxy statement (as it may be amended, the "Proxy Statement") with the U.S. Securities and
Exchange Commission (the "SEC") in connection with such solicitation of proxies from Forest shareholders.
FOREST SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT AND
ACCOMPANYING PROXY CARD AS THEY CONTAIN IMPORTANT INFORMATION. Detailed information
regarding the identity of participants, and their direct or indirect interests, by security holdings or otherwise,
is set forth in the Proxy Statement, including Appendix B thereto. Shareholders can obtain the Proxy
Statement, any amendments or supplements to the Proxy Statement and other documents filed by Forest
Laboratories with the SEC for no charge at the SEC's website at www.sec.gov. Copies are also available at no
charge at Forest Laboratories' website at www.frx.com or by writing to Forest Laboratories at 909 Third
Avenue, New York, New York 10022.
|